Pridopidine Pivotal Phase 3 ALS Study Unveiled at NEALS 2025 Annual Meeting
NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain, October 07, 2025 — Prilenia Therapeutics B.V. and Ferrer today announced the presentation of their planned pivotal Phase 3 study of pridopidine in Amyotrophic Lateral Sclerosis (ALS) […]
